…
…
ROE = tax × interest × margin × turnover × leverage
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Tax burden | 0.86x | 0.82x | 0.91x | 0.87x | 0.71x |
| Interest burden | 1.00x | 1.00x | 1.00x | 1.00x | 1.00x |
| Operating margin | 8.5% | 7.0% | 7.7% | 6.5% | 8.3% |
| Asset turnoverdriver | 1.86x | 2.03x | 2.10x | 2.17x | 2.18x |
| Leverage (equity mult.) | 1.82x | 1.94x | 1.85x | 1.91x | 1.82x |
| = Return on Equity (consolidated) | 24.4% | 22.4% | 27.1% | 23.4% | 23.3% |
| Return on Invested Capital (ROIC) | 24.5% | 22.5% | 27.2% | 23.5% | 23.4% |
Consolidated (pre-minority-interest) basis; the headline ROE in the ratio grid is owners’ basis.
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Current Ratio(Current Assets / Current Liabilities) | 1.88x | 1.69x | 1.72x | 1.63x | 1.76x |
| Quick Ratio((Current Assets − Inventory) / Current Liabilities) | 1.04x | 0.88x | 0.85x | 0.67x | 0.73x |
| Cash Ratio(Cash / Current Liabilities) | 0.81x | 0.13x | 0.12x | 0.10x | 0.23x |
| Working Capital(Current Assets − Current Liabilities) | Rp 19 T | Rp 17 T | Rp 17 T | Rp 15 T | Rp 16 T |
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Debt to Equity (DER)(Total Debt / Total Equity) | 0.01x | 0.02x | 0.02x | 0.02x | 0.01x |
| Liabilities to Equity(Total Liabilities / Total Equity) | 0.82x | 0.94x | 0.85x | 0.91x | 0.82x |
| Debt to Assets(Total Debt / Total Assets) | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
| Net Debt(Total Debt − Cash) | -Rp 17 T | -Rp 2.8 T | -Rp 2.2 T | -Rp 1.9 T | -Rp 4.4 T |
| Interest Coverage(EBIT / Interest Expense) | 276.74x | 351.68x | 362.45x | 279.90x | 333.39x |
| Equity Multiplier (Assets ÷ Equity) | 1.82x | 1.94x | 1.85x | 1.91x | 1.82x |
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Gross Margin(Gross Profit / Revenue) | 17.0% | 15.4% | 16.7% | 15.7% | 18.4% |
| Operating Margin(EBIT / Revenue) | 8.5% | 7.0% | 7.7% | 6.5% | 8.3% |
| Net Margin(Net Income / Revenue) | 7.2% | 5.7% | 7.0% | 5.6% | 5.9% |
| EBITDA(EBIT + D&A) | Rp 9.4 T | Rp 8.7 T | Rp 9.9 T | Rp 8.7 T | Rp 10 T |
| EBITDA Margin(EBITDA / Revenue) | 9.5% | 7.8% | 8.5% | 7.4% | 9.3% |
| Return on Assets (ROA)(Net Income / Total Assets) | 13.4% | 11.5% | 14.6% | 12.2% | 12.8% |
| Return on Equity (ROE)(Net Income (Owners) / Equity (Owners)) | 24.4% | 22.4% | 27.1% | 23.4% | 23.3% |
| Tax Burden (Net ÷ Pretax) | 0.86x | 0.82x | 0.91x | 0.87x | 0.71x |
| Interest Burden (Pretax ÷ EBIT) | 1.00x | 1.00x | 1.00x | 1.00x | 1.00x |
| Return on Invested Capital (ROIC) | 24.5% | 22.5% | 27.2% | 23.5% | 23.4% |
| Turnover | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Asset Turnover(Revenue / Total Assets) | 1.86x | 2.03x | 2.10x | 2.17x | 2.18x |
| Inventory Turnover(COGS / Inventory) | 4.43x | 4.75x | 4.76x | 4.38x | 4.28x |
| Receivables Turnover(Revenue / Receivables) | 41.53x | 37.75x | 35.31x | 33.67x | 36.72x |
| Payables Turnover(COGS / Payables) | 19.89x | 17.82x | 14.46x | 15.35x | 17.22x |
| Conversion Period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Days Inventory Outstanding (DIO)(365 × Inventory / COGS) | 82.3 days | 76.9 days | 76.6 days | 83.3 days | 85.3 days |
| Days Sales Outstanding (DSO)(365 × Receivables / Revenue) | 8.8 days | 9.7 days | 10.3 days | 10.8 days | 9.9 days |
| Days Payable Outstanding (DPO)(365 × Payables / COGS) | 18.3 days | 20.5 days | 25.2 days | 23.8 days | 21.2 days |
| Cash Conversion Cycle (CCC)(DIO + DSO − DPO) | 72.8 days | 66.0 days | 61.7 days | 70.3 days | 74.0 days |
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Free Cash Flow(Operating Cash Flow − Capex) | Rp 9.9 T | Rp 5.2 T | Rp 4.6 T | Rp 3.3 T | Rp 6.7 T |
Price Rp 735 · market cap Rp 85 T
| Multiple | HMSP | Peer median | vs median |
|---|---|---|---|
| P/E | 12.93x | 12.93x | 0% |
| P/B | 3.02x | 1.61x | +87% |
| P/S | 0.76x | 0.56x | +37% |
| EV/EBITDA | 7.79x | 5.74x | +36% |
| EV/EBIT | 8.74x | 8.74x | 0% |
| EV/Sales | 0.72x | 0.56x | +29% |
| FCF Yield | 7.78% | 7.78% | 0% |
| Dividend Yield | 7.65% | 3.80% | +101% |
Only 3 peers are covered here, so the median is itself one of the members. A 0% gap can simply mean HMSP sits at the median.
EV = mkt cap Rp 85 T + debt Rp 415 M − cash Rp 4.8 T = Rp 81 T
At today’s price, the market is paying for 7.4%/yr FCF growth (4.3% at 12.0% to 10.2% at 16.0% discount rates). Delivered over the last 4 years: -9.4% FCF · 3.2% revenue.
Reverse DCF: single-stage FCF, terminal growth 2.5%, discount band 12.0–16.0% (β=1; build cited in Methodology). Not a forecast.
This model projects the operating cash the whole business generates, discounts it back at the blended cost of capital, and subtracts net debt. What remains is the equity value, stated per share. Every input below comes from the company's own audited record or from cited market data, and you can adjust each one yourself.
Base year contains named one-off item(s): FY2025: Second consecutive year with no increase in tobacco excise or the minimum retail price; FY2023: Two years where operating cash flow fell below reported profit. The EBIT basis screens out most non-operating items, but read the Earnings Quality section before trusting the base margin.
| Assumption | Value | Basis |
|---|---|---|
| Rf (risk-free) | 7.26% | Indonesia 10Y government bond, 8 Jul 2026 |
| ERP (Rm − Rf) | 6.69% | Damodaran Indonesia, Jul 2026 (Baa2, CRP 2.46%) |
| β | 0.68 → 0.68 | Tobacco (unlevered) relevered at own D/E 0.00 |
| Cost of equity | 11.83% | Rf + β × ERP |
| Cost of debt | 6.71% | FY2025 interest expense ÷ total debt |
| Tax rate | 14.4% | median effective rate, FY2021–FY2025 (pretax ≈ EBIT − interest) |
| WACC | 11.80% | 100% E × CoE + 0% D × Kd × (1 − t) |
| Revenue growth (yr 1, fading) | 3.2% | delivered 4-yr revenue CAGR 3.2%, fading linearly to terminal |
| EBIT margin | 7.5% | mean EBIT margin, last 3 FYs |
| D&A / revenue | 0.9% | mean D&A/revenue, last 3 FYs |
| Capex / revenue | 1.2% | mean capex/revenue, last 3 FYs, for the explicit years; in the terminal year capex falls to replacement level (equal to depreciation, 0.9% of revenue) because holding a build-phase or pause-phase ratio in perpetuity misprices the company in whichever direction that phase points |
| ΔNWC / Δrevenue | 7.9% | median ΔNWC/Δrevenue across the seeded years (NWC = AR + inventory − AP) |
| Terminal growth | 2.5% | BI inflation-target midpoint (2.5% ± 1%) |
| Year | +1 | +2 | +3 | +4 | +5 | T∞ |
|---|---|---|---|---|---|---|
| Growth | 3.2% | 3.0% | 2.9% | 2.7% | 2.5% | 2.5% |
| Revenue | Rp 116 T | Rp 119 T | Rp 123 T | Rp 126 T | Rp 129 T | Rp 132 T |
| EBIT | Rp 8.7 T | Rp 9.0 T | Rp 9.2 T | Rp 9.5 T | Rp 9.7 T | Rp 9.9 T |
| NOPAT | Rp 7.4 T | Rp 7.7 T | Rp 7.9 T | Rp 8.1 T | Rp 8.3 T | Rp 8.5 T |
| + D&A | Rp 1.0 T | Rp 1.0 T | Rp 1.1 T | Rp 1.1 T | Rp 1.1 T | Rp 1.1 T |
| − Capex | Rp 1.4 T | Rp 1.5 T | Rp 1.5 T | Rp 1.5 T | Rp 1.6 T | Rp 1.1 T |
| − ΔNWC | Rp 284 M | Rp 277 M | Rp 268 M | Rp 259 M | Rp 248 M | Rp 255 M |
| FCFF | Rp 6.7 T | Rp 7.0 T | Rp 7.2 T | Rp 7.4 T | Rp 7.6 T | Rp 8.3 T |
| PV | Rp 6.0 T | Rp 5.6 T | Rp 5.1 T | Rp 4.7 T | Rp 4.3 T | Rp 51 T |
Check it yourself: revenue × margin = EBIT · NOPAT = EBIT × (1 − tax) · FCFF = NOPAT + D&A − Capex − ΔNWC · PV = FCFF ÷ (1+WACC)^yr · TV = FCFF(T∞) ÷ (WACC − g), discounted from year 5
EV = PV(explicit) Rp 26 T + PV(TV) Rp 51 T = Rp 77 T · TV 66% of EV · − net debt -Rp 4.4 T − minority Rp 0
Model output: Rp 696/share (-5% vs price Rp 735)· exit-multiple check (5.7x): Rp 565
Under these assumptions the model lands close to today's price. The market and these inputs are telling broadly the same story.
| g \ WACC | 10.8% | 11.8% | 12.8% |
|---|---|---|---|
| 2.0% | 743 | 669 | 610 |
| 2.5% | 777 | 696 | 631 |
| 3.0% | 817 | 727 | 655 |
Model output under the stated assumptions. Every input above comes from the company's own audited record or from cited market data, and every one can be adjusted. This is not a price target and not advice.
Educational analysis. Multiples pair today’s price with the latest audited fiscal year (trailing-FY convention); peer figures are the covered peer sample, not the whole market. Never a price target.
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | Rp 99 T | Rp 111 T | Rp 116 T | Rp 118 T | Rp 112 T |
| Cost of Goods Sold | Rp 82 T | Rp 94 T | Rp 97 T | Rp 99 T | Rp 92 T |
| Gross Profit | Rp 17 T | Rp 17 T | Rp 19 T | Rp 19 T | Rp 21 T |
| Operating Income (EBIT) | Rp 8.4 T | Rp 7.8 T | Rp 9.0 T | Rp 7.7 T | Rp 9.3 T |
| Interest Expense | Rp 30 M | Rp 22 M | Rp 25 M | Rp 28 M | Rp 28 M |
| Net Income | Rp 7.1 T | Rp 6.3 T | Rp 8.1 T | Rp 6.6 T | Rp 6.6 T |
| Net Income Attributable to Owners | Rp 7.1 T | Rp 6.3 T | Rp 8.1 T | Rp 6.6 T | Rp 6.6 T |
| Depreciation & Amortization | Rp 992 M | Rp 914 M | Rp 903 M | Rp 972 M | Rp 1.1 T |
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | Rp 18 T | Rp 3.3 T | Rp 2.7 T | Rp 2.4 T | Rp 4.8 T |
| Accounts Receivable | Rp 2.4 T | Rp 2.9 T | Rp 3.3 T | Rp 3.5 T | Rp 3.1 T |
| Inventory | Rp 19 T | Rp 20 T | Rp 20 T | Rp 23 T | Rp 21 T |
| Current Assets | Rp 41 T | Rp 41 T | Rp 40 T | Rp 39 T | Rp 36 T |
| Total Assets | Rp 53 T | Rp 55 T | Rp 55 T | Rp 54 T | Rp 52 T |
| Accounts Payable | Rp 4.1 T | Rp 5.3 T | Rp 6.7 T | Rp 6.5 T | Rp 5.3 T |
| Current Liabilities | Rp 22 T | Rp 25 T | Rp 23 T | Rp 24 T | Rp 21 T |
| Total Liabilities | Rp 24 T | Rp 27 T | Rp 25 T | Rp 26 T | Rp 23 T |
| Total Interest-Bearing Debt | Rp 426 M | Rp 531 M | Rp 522 M | Rp 473 M | Rp 415 M |
| Total Equity | Rp 29 T | Rp 28 T | Rp 30 T | Rp 28 T | Rp 28 T |
| Equity Attributable to Owners | Rp 29 T | Rp 28 T | Rp 30 T | Rp 28 T | Rp 28 T |
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Operating Cash Flow | Rp 10 T | Rp 7.4 T | Rp 6.3 T | Rp 5.2 T | Rp 7.4 T |
| Capital Expenditure | Rp 412 M | Rp 2.2 T | Rp 1.7 T | Rp 1.8 T | Rp 755 M |
HM Sampoerna is the market leader (~28% share), majority-owned by Philip Morris International, and structurally the most profitable tobacco name in Indonesia. It earns ROE ~23–27% on a gross margin of ~15–18% (measured on filed revenue, which includes excise), carries almost no debt (D/E 0.015), and pays out a high dividend. Its premium brands (Sampoerna A/Mild, Dji Sam Soe, licensed Marlboro) and an asset-light model deliver returns far above GGRM’s, whose gross margin runs only ~9–12%. It is not immune to the sector’s headwinds: annual excise hikes and down-trading dented margins in FY24 before a FY25 recovery (gross margin back to 18.4%). This is the quality tobacco leader, with PMI’s backing and reduced-risk-product optionality (IQOS); the factors that swing it are excise policy and its ability to defend premium share.
Tobacco leaf is bought, graded and aged before it can be blended, so inventory is a production input rather than unsold stock. Days inventory ran 82.3, 76.9, 76.6, 83.3 and 85.3 across FY2021 to FY2025.
EconomicsThat ageing requirement is why the cash cycle is 74 days despite selling a fast-moving consumer product: suppliers are paid in about 21 days while stock sits for 85.
Excise bands are the single largest cost in Indonesian tobacco and are paid on production, not on collection from retailers. Cost of revenue was 81.6 percent of sales in FY2025, and excise is the bulk of it.
EconomicsRead this as a working-capital tax as much as a profit tax. It also means the government, not the company, sets the largest line in the income statement.
Retail price must clear the excise band plus margin, so pricing power is exercised inside a regulated corridor. After two years with no excise increase, HMSP raised prices only modestly: Marlboro Red by 2.5 percent, Sampoerna Kretek 2.4 percent, A Mild 1.7 percent.
EconomicsFY2025 shows what that corridor is worth. Revenue FELL 4.8 percent to IDR 112.2tn, yet gross profit ROSE 11.2 percent and operating profit 20.6 percent, because price held while volume gave way.
Product reaches several hundred thousand outlets, mostly small independent stores, on short credit. Days sales outstanding was only 9.9 in FY2025.
EconomicsTen-day receivables against 85-day inventory is the signature of this model: the hard capital is committed upstream in leaf, not downstream in trade credit.
Cost structureExcise dominated. Cost of revenue was IDR 91.6tn of IDR 112.2tn in FY2025, leaving an 18.4 percent gross margin, and the improvement from 15.7 percent in FY2024 is almost entirely the excise freeze rather than manufacturing gains. Below that, operating margin of 8.3 percent means roughly 10 points of the gross margin goes to selling and distribution, which is what a national outlet network costs. Interest is immaterial at IDR 27.8bn against IDR 9.3tn of operating profit, giving cover of 333 times.
Cash cycleLong by consumer-goods standards and stable: the cash conversion cycle ran 72.8, 66.0, 61.7, 70.3 and 74.0 days. The composition is what matters. Inventory sits 85.3 days because leaf must age, receivables clear in 9.9 days because the trade pays fast, and payables run only 21.2 days. So HMSP funds its own inventory rather than pushing it onto suppliers, the opposite of the minimarket model.
Unit economicsA 5.9 percent net margin that produces a 23.3 percent return on equity, and the bridge is turnover plus the absence of debt. Assets turn 2.18 times a year and debt to equity is 1.5 percent, so return on invested capital of 23.4 percent is almost identical to return on equity: there is no leverage doing the work. Compare that with BREN on this site, where a 71 percent margin produced single-digit returns because turnover was 0.16 times. HMSP is the same arithmetic run the other way, and it is why a low-margin regulated business can still compound.
Tobacco/clove farmers plus the government via excise drive costs; PMI scale aids sourcing.
Implication → Excise remains the largest, rising cost, but premium pricing absorbs it better than peers.
Smokers down-trade to cheaper brands, pressuring HMSP’s premium mix.
Implication → The main threat to its margin premium: defending share against value brands is key.
Brand scale, distribution, excise licensing and PMI backing are high barriers.
Implication → Market leadership is defensible; the premium franchise is hard to replicate.
Cheaper tiers, illicit cigarettes and vaping substitute; PMI’s IQOS is HMSP’s own reduced-risk hedge.
Implication → Down-trading erodes mix, but reduced-risk products offer a long-term option.
Intense competition with GGRM and value brands on price/tier amid shrinking legal volumes.
Implication → Pressures share and mix, especially as consumers trade down.
Clean and unusually easy to read, which makes the one distortion worth isolating. Returns are stable to the point of monotony: return on equity 24.4, 22.4, 27.1, 23.4 and 23.3 percent, with return on invested capital within a tenth of a point of it every year because there is effectively no debt. There are no acquisition gains, no revaluations and no minority interests at all, so reported profit is owners profit. The distortion is below the operating line in FY2025. Operating profit rose 20.6 percent, yet net profit was flat at IDR 6.6tn, because the share of pre-interest profit retained after tax and other items fell from 86.6 percent to 71.4 percent. Read the operating line for the business and the retained share for the tax and other-items wedge; conflating them makes a good operating year look like a flat one. The structural caution is not accounting, it is the mix: between 2019 and 2024 machine-made kretek fell from 74 percent to 49 percent of national tobacco excise revenue while hand-rolled kretek rose from 19 to 42 percent, which is consumers trading down the price ladder, and that migration works against a portfolio weighted to premium machine-made brands.
| Period | One-off item | Impact |
|---|---|---|
| FY2025 | Second consecutive year with no increase in tobacco excise or the minimum retail price | The freeze let price rise faster than volume fell: revenue DOWN 4.8 percent to IDR 112.2tn while gross profit rose 11.2 percent and operating profit 20.6 percent, with gross margin recovering from 15.7 to 18.4 percent. This is a policy windfall rather than an operating improvement, and it reverses whenever the excise band moves again. |
| FY2023 | Two years where operating cash flow fell below reported profit | Operating cash flow covered only 0.78 times net profit in FY2023 and again in FY2024, against 1.44 times in FY2021, as inventory days climbed from 76.6 to 83.3. Cash conversion recovered to 1.12 times in FY2025. Watch leaf inventory as the swing item, since it is the only large use of working capital in this model. |
Cash conversionGood across the window and never structurally impaired: operating cash flow covered net profit 1.44, 1.16, 0.78, 0.78 and 1.12 times, and free cash flow was POSITIVE every year at IDR 9.9tn, 5.2tn, 4.6tn, 3.3tn and 6.7tn. Capital spending is trivial for a manufacturer at 0.4 to 2.0 percent of revenue, so almost all operating cash is distributable. That is the real argument for this business: it converts a regulated, declining-volume category into cash with very little reinvestment.
An almost pure harvester, and the balance sheet shows it was designed that way. Equity has not grown in five years, sitting at IDR 29.2tn in FY2021 and IDR 28.4tn in FY2025, while the company earned IDR 34.8tn of cumulative net profit over the same period. Nearly all of it left the business. Total assets actually SHRANK from IDR 53.1tn to IDR 51.6tn. This is not stagnation by accident; it is a mature category being run for cash.
DeploymentThere is very little to deploy and management does not pretend otherwise. Capital spending ran IDR 0.4tn, 2.2tn, 1.7tn, 1.8tn and 0.8tn, never above 2.0 percent of revenue. Debt is a rounding error at IDR 415bn against IDR 28.4tn of equity, so there is no refinancing story and no interest-rate sensitivity. Cash rose from IDR 2.4tn to IDR 4.8tn in FY2025 as the excise freeze fattened margins. The allocation question for a harvester is only ever whether the cash is returned or hoarded, and the flat equity base answers it.
Returns trendReturns are the most stable in the roster: return on equity between 22.4 and 27.1 percent for five straight years, with return on invested capital tracking within a tenth of a point because there is no debt. Very few businesses here clear their cost of equity by that margin that consistently. Now the valuation, and it is genuinely unusual. At IDR 734.96 per share the market capitalisation of about IDR 85.5tn sits against a forward discounted cash flow value of IDR 696.47, a gap of MINUS 5.2 percent. After six deep names on this site where model and price diverged by 80 to 750 percent, here is one where they very nearly agree. Do not read that as precision; read it as the absence of an argument. The reverse model implies about 7.4 percent free cash flow growth against minus 9.4 percent actually delivered, so the price already assumes the volume decline stops, and the EV/EBITDA of 7.3 times against a 5.3 times tobacco peer median is a 37 percent premium. The bull and bear cases here are about excise policy and downtrading, not about mispricing.
Excise is the bulk of a cost of revenue that ran 81.6 percent of sales in FY2025, and it is paid on production rather than on collection. FY2025 earnings improved mainly because the excise band and minimum retail price were frozen for a second consecutive year, not because the business got better. When the band moves again the margin recovery from 15.7 to 18.4 percent reverses, and the company has no ability to refuse the increase.
Between 2019 and 2024 machine-made kretek fell from 74 percent to 49 percent of national tobacco excise revenue while hand-rolled kretek rose from 19 percent to 42 percent. That is structural downtrading, not a cyclical dip, and it runs against a portfolio weighted to premium machine-made brands. Revenue has now fallen for a year, from IDR 117.9tn to IDR 112.2tn, and the government plans to expand tax tiers, which changes the shape of the ladder again.
FY2025 operating profit rose 20.6 percent while net profit was flat at IDR 6.6tn, because the share of pre-interest profit retained after tax and other items fell from 86.6 percent to 71.4 percent. Anyone reading only the bottom line will conclude nothing happened, and anyone reading only the operating line will miss that the improvement did not reach shareholders. Both lines are needed here.
Equity was IDR 29.2tn in FY2021 and IDR 28.4tn in FY2025 while the company earned IDR 34.8tn cumulatively, and total assets shrank. Capital spending never exceeded 2.0 percent of revenue. That is the correct strategy for a mature regulated category, but it means the entire return depends on cash being returned and on volume declining slowly. There is no reinvestment option to fall back on if the category contracts faster.
Inventory sits 85.3 days because tobacco must age, while suppliers are paid in 21.2 days and customers pay in 9.9. HMSP therefore funds its own stock, which is why operating cash flow fell to 0.78 times profit in both FY2023 and FY2024 when inventory days climbed. It is a manageable and well-understood cycle, but it is the one place where a demand shock turns quickly into a cash problem.
Curated narrative (educational interpretation), backed by the linked sources. The figures above are deterministic. Not investment advice.
The world’s second-largest cigarette market (~USD34bn, kretek-dominated): a high-volume, excise-squeezed, structurally-declining industry whose biggest player (Djarum) is private.